MedTrace Logo

To Evaluate the Efficacy and Safety of ABCD in the Treatment of IFD

NCT05116059 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-10-21

No results posted yet for this study

Summary

In order to better guide clinical medication, verify the efficacy and safety of ABCD in the treatment of various invasive fungal disease, the investigators have designed a multi-center, retrospective registration study. Diagnosis and treatment data for patients with different types of invasive fungal disease in clinical actual environment was collapsed by a database for collaborative exchange on antifungal research.

Conditions

  • Invasive Fungal Disease

Interventions

DRUG

Amphotericin B colloidal dispersion（ABCD）

The dosage and course of ABCD were determined by clinicians, and this study was registered according to clinical practice

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • zhengyin Liu, PhD · Peking Union Medical College Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-22
Primary Completion
2022-12-31
Completion
2023-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05116059 on ClinicalTrials.gov